You have requested a machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Neither SPIE nor the owners and publishers of the content make, and they explicitly disclaim, any express or implied representations or warranties of any kind, including, without limitation, representations and warranties as to the functionality of the translation feature or the accuracy or completeness of the translations.
Translations are not retained in our system. Your use of this feature and the translations is subject to all use restrictions contained in the Terms and Conditions of Use of the SPIE website.
14 March 2018Clinical trial results using fluorescently labeled antibodies (Conference Presentation)
Over the past two decades, synergistic innovations in imaging technology have resulted in a revolution in which a range of biomedical applications are now benefiting from fluorescence imaging. Fluorescence imaging of lymph nodes after systemic cetuximab-IRDye800CW administration demonstrated high sensitivity and was capable of identifying additional positive nodes on deep sectioning.
The alert did not successfully save. Please try again later.
Eben L. Rosenthal M.D., Nynke van den Berg, Tarn Teraphongphom, Jason Warram, "Clinical trial results using fluorescently labeled antibodies (Conference Presentation)," Proc. SPIE 10469, Optical Imaging, Therapeutics, and Advanced Technology in Head and Neck Surgery and Otolaryngology 2018, 104690E (14 March 2018); https://doi.org/10.1117/12.2297305